Stuart Cobb - 14 May 2025 Form 4 Insider Report for Neurogene Inc. (NGNE)

Role: Chief Scientific Officer
Signature: /s/ Donna M Cochener, as attorney-in-fact for Stuart Cobb
Issuer symbol: NGNE
Transactions as of: 14 May 2025
Net transactions value: -$103,003
Form type: 4
Filing time: 15 May 2025, 16:43:07 UTC
Previous filing: 28 Mar 2025
Next filing: 24 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Cobb Stuart	Chief Scientific Officer	C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR, NEW YORK	/s/ Donna M Cochener, as attorney-in-fact for Stuart Cobb	15 May 2025	0001994301

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NGNE	Common Stock	Sale	$103,003	-6,797	-25%	$15.15	20,794	14 May 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.
F2	The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.78 to $15.75. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.78 to $15.75. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.